Osimertinib Plus Chemo May Be Effective After Progression on Osimertinib
Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced non-small-cell lung cancer (NSCLC) who had disease progression on first-line treatment with osimertinib.
According to research presented at the 2025 World Conference on Lung Cancer, progression on first-line osimertinib may be heterogeneous, with some cells retaining their EGFR-signaling dependence and sensitivity to EGFR tyrosine kinase inhibitors, explained study presenter Giulia Pasello, MD, PhD, of the University of Padua in Italy.
Progression on first-line osimertinib may be heterogeneous, with some cells retaining their EGFR-signaling dependence and sensitivity to EGFR tyrosine kinase inhibitors.
Dr Pasello and colleagues evaluated whether continuing osimertinib after progression and adding chemotherapy could improve outcomes over second-line chemotherapy alone in the phase 3 COMPEL trial (NCT04765059).
Author summary: Osimertinib plus chemo may improve NSCLC outcomes.
More News
- Former Auburn coach Bruce Pearl to become national TV analyst
- Who knew that the public would end up supporting striking teachers? Not Danielle Smith and the UCP! - Alberta Politics
- Is Lady Louise Windsor the saving grace of the royal family? How the ‘dark horse’ daughter of the Duke and Duchess of Edinburgh could soon enter the spotlight
- DOJ to officially ask grand jury to indict former Trump advisor John Bolton
- 2026 Toyota GR Supra Final Edition First Drive Review
- Liam Payne’s Final Days in Argentina, One Year After His Death: Fans, Concerts, Bowling, and Excess
- Bella Hadid makes dazzling blonde comeback to Victoria's Secret Fashion Show
- “Brewers Karen” Loses Her Job After She Was Caught On Video Saying “Let’s Call ICE” On An American War Veteran At NLCS Game
- ‘I Feel Really Excited’ – Nong-O Says Rodtang Title Fight Is The Biggest Of His Career
- Barbie Ferreira’s Victoria’s Secret runway debut is this generation’s 'Angel energy'